A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β

Cancer

Volumn 117, Issue 4, 2011, Pages 826-831

  Grignani, Giovanni ^a   Palmerini, Emanuela ^b   Stacchiotti, Silvia ^c   Boglione, Antonella ^d   Ferraresi, Virginia ^e   Frustaci, Sergio ^f   Comandone, Alessandro ^d   Casali, Paolo G ^c   Ferrari, Stefano ^b   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d GRADENIGO HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f Department of Medical Oncology   (Italy)

Author keywords

chondrosarcoma; imatinib mesylate; PDGFR ; platelet derived growth factor receptor (PDGFR) ; targeted therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ARTICLE; CHONDROSARCOMA; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MALE; MULTICENTER STUDY; MUSCLE CRAMP; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; RECURRENT CANCER; TREATMENT OUTCOME; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG EFFICACY; DRUG SAFETY; OPEN STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHONDROSARCOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECURRENCE; TREATMENT OUTCOME;

EID: 79551701930     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25632     Document Type: Article

References (30)

1. Bertoni F, Bacchini P, Milchgrub S, Hogendoorn PCW., Chondrosarcoma. In:, Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002: 247-254.
2. Gelderblom H, Hogendoorn PCW, Dijkstra D, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008; 13: 320-329.
3. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009; 74: 732-739.
4. Schulz-Ertner D, Nikoghosyan A, Hof H, et al. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys. 2007; 67: 171-177.
5. Dickey ID, Rose PS, Fuchs B, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am. 2004; 86 -A: 2412-2418.
6. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Bone Cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2010. Available at:. Accessed April 2010.
7. Sulzbacher I, Birner P, Trieb K, et al. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol. 2001; 25: 1520-1527.
8. Bovee JV, Cleton-Jansen AM, Taminiau AH, et al. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol. 2005; 6: 599-607.
9. Lagonigro MS, Tamborini E, Negri T, et al. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol. 2006; 208: 615-623.
10. Demetri GD, Von Meheren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480.
11. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002; 20: 3586-3591.
12. Casali PG, Messina A, Stacchiotti S, et al. Imatinib in chordoma. Cancer. 2004; 101: 2086-2097.
13. National Cancer Institute. The NCI Common Terminology Criteria for Adverse Events (CTCAE).Version 3.0. Bethesda, MD: National Cancer Institute; Year. Available at:. Access date.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
15. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753-1759.
16. Caraceni A, Mendoza TR, Mencaglia E, et al. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain. 1996; 65: 87-92.
17. Simon R., Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
18. Staals EL, Bacchini P, Mercuri M, et al. Dedifferentiated chondrosarcoma arising in preexisting osteochondromas. J Bone Joint Surg Am. 2007; 89: 987-993.
19. Dantonello TM, Int-Veen C, Leuschner I, et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer. 2008; 112: 2424-2431.
20. Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVMS/TGCT). Ann Oncol. 2008; 19: 821-822.
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
22. Tamborini E, Miselli F, Negri T, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res. 2006; 12: 6920-6928.
23. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008; 216: 64-74.
24. Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA. 2008; 105: 8387-8392.
25. Wozniak A, Sciot R, Guillou l, et al. Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer. 2007; 46: 261-276.
26. Hallor KH, Staaf J, Bovee JVMG, et al. Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res. 2009; 15: 2685-2694.
27. Maurel J, Martins AS, Poveda A, et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer. 2010; 116: 3692-3701.
28. Schrage YM, Briaire-de Bruijn IH, de Mirando NFCC, et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res. 2009; 69: 6216-6222.
29. Schrage YM, Machado I, Meijer D, et al. COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Eur J Cancer. 2010; 46: 616-624.
30. Bovée JV, van den Broek LJ, Cleton-Jansen AM, et al. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest. 2000; 80: 1587-1595.